Empagliflozin for treating chronic kidney disease - guidance (TA942)

NICE recommends empagliflozin for chronic kidney disease (CKD) in adults as an add-on to optimised standard care including the highest tolerated licensed dose of ACEi/ARB, unless contraindicated. Restricted to use under set renal function criteria (eGFR & urine-creatinine ratio).

SPS commentary:

Restricted to use where:

  • eGFR is ≥20 ml/min/1.73m2 <45 ml/min/1.73m2 or
  • eGFR is ≥45 ml/min/1.73m2 <90 ml/min/1.73m2 and either: the urine albumin-to-creatinine ratio is ≥22.6 mg/mmol, or patient has type 2 diabetes.

National Institute for Health and Care Excellence